SOPHiA GENETICS Announces Launch Of DEEP-Lung-IV Multimodal Clinical Study
SOPHiA GENETICS SA (NASDAQ:SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today the launch of their DEEP-Lung-IV clinical study
Sophia Genetics Q3 Adj. EPS $(0.30) Beats $(0.36) Estimate, Sales $10.40M Beat $9.90M Estimate
Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 50 percent decrease over losses of $(0.20) per share from the
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Sophia Genetics Launches SOPHiA DDM For SureSelect Human All Exon v8
SOPHiA GENETICS SA (NASDAQ:SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today they have extended their SOPHiA DDM™ Universal
SOPHiA GENETICS Highlights Launch Of Its SOPHiA Clinical Exome Solution v3 For Deeper Investigation Of Mendelian Diseases
SOPHiA GENETICS SA (NASDAQ:SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today the launch of SOPHiA Clinical Exome Solution v3, a new
Sophia Genetics Q2 EPS $(0.31) Beats $(0.39) Estimate, Sales $10.18M Beat $8.60M Estimate
Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.39) by 20.51 percent. The company reported quarterly sales of $10.18 million which beat the
Earnings Scheduled For September 9, 2021
Companies Reporting Before The Bell
• Li-Cycle Holdings (NYSE:LICY) is likely to report earnings for its third quarter.
Dasa Expands partnership With SOPHiA GENETICS For first decentralized Cancer Biomarker Detection Solution In Latin America
Dasa, the largest integrated healthcare network in Brazil, has chosen to expand upon its partnership with SOPHiA GENETICS SA (NASDAQ:SOPH) to offer the first decentralized HRD (Homologous recombination deficiency)